Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market for duodenal cancer is characterized by relatively low incidence rates compared to other gastrointestinal cancers. Limited awareness about duodenal cancer contributes to challenges in early detection and treatment. The low prevalence impacts market dynamics, influencing research focus and resource allocation.
The complexity of diagnosing and identifying duodenal cancer presents a major difficulty. Signs may be non-specific, hence the diagnosis is delayed. Diagnostic technologies advancements and attempts of educating healthcare practitioners are very important for the dynamics of the market and the rates of early detection.
In surgical methods duodenectomy is normally the primary treatment of duodenal cancer. Surgical procedures demand affects market dynamics, and advances in surgical procedures tend to affect patient outcomes and recovery. The surgery dictates duodenal cancer treatment.
The market is constrained by little therapies options for duodenal cancer. Major research lines of inquiry are aimed at finding efficient treatments that include chemo and target therapies. The lack of specific remedies impacts market dynamics, with pharmaceutical innovations providing the possibility of new breakthroughs.
Sometimes duodenal cancer is combined with Gastrointestinal Stromal Tumors (GIST). This linkage affects market dynamics since the evolution of treatments for GIST due to the market potential of duodenal cancer. Joint research activities probe common pathways and therapeutic modalities.
Immunotherapy is drawing the focus in the midst of the treatment scene of different types of cancers among which is the duodenal cancer. The development of immunotherapeutic approaches influence market dynamics providing alternative for patients who are not responsive to the traditional treatments. Continued research influences the development of new treatment paradigms.
Duodenal cancer being a rare disease may result in the orphan drug designation of the particular therapies. The regulatory incentives that are associated with an orphan drug are the driving forces you cancer duodenal case study in cancer pharmaceutical company spend its money in research and development.
Progress in genetic and molecular profiling helps in studying the molecular features of duodenal tumor. This information affects the targeted therapies and individualized treatment strategies. The precision medicine approach influences market dynamics through delivery of customized solutions to the patient level.
Global disparities in healthcare infrastructure affect duodenal cancer market dynamics. The availability of modern diagnostic facilities, surgical proficiency and new treatment options differ from region to region. The approach to these discrepancies becomes essential in creating a more even duodenal cancer care landscape.
Patient advocacy and support organizations play a role in influencing market dynamics. These organizations raise awareness, support research initiatives, and advocate for improved patient care. Their impact on policy changes and public awareness contributes to the evolving landscape of duodenal cancer.
Duodenal Cancer Market Highlights:
Duodenal Cancer Market Scenario
The duodenal cancer market is projected to reach USD 3.85 Billion by 2030 at CAGR 12.54% during the forecast period 2022-2030 Duodenal cancer, also known as the small bowel cancer, are caused in the duodenum area of the small intestine.
Numerous factors such as the growing prevalence of rare cancers, rising prevalence of chronic diseases, increasing, technological advancements and growing geriatric population are expected to drive the growth of the market. For instance, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Moreover, favorable healthcare expenditures boost the growth of the market. However, stringent government regulation for product approval and the high cost of the treatments may hamper the market growth during the assessment period.
Segmentation
The duodenal cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into adenocarcinoma, sarcoma, neuroendocrine (carcinoid) tumors, and lymphoma.
The market, by diagnosis, has been segmented into endoscopy or colonoscopy, capsule endoscopy, barium X-ray, CT scan, MRI scan, and other tests.
The market, by treatment, has been segmented into surgery, radiotherapy, and chemotherapy.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The duodenal cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European duodenal cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.Â
The duodenal cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The duodenal cancer market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, Ipsen Biopharmaceuticals Inc., Thermo Fisher Scientific, Abbott, G E Healthcare, Agilent Technologies Inc., AstraZeneca, Boehringer Ingelheim International GmbH, and Bayer AG are some of the key players in the duodenal cancer market.
Regional Market Summary
Duodenal Cancer Market Share (%), by Region, 2017
Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)
Geographically, the Americas is anticipated to dominate the duodenal cancer market owing to a well-developed healthcare sector, rising prevalence of rare and chronic disease and growing healthcare expenditure. According to an article published by, American Society of Clinical Oncology (ASCO) in January 2018, 67% of people diagnosed with duodenal cancer survive it for five years. Europe is expected to hold the second largest position in the duodenal cancer market. The market growth in this region is attributed to the growing prevalence of chronic diseases, availability of funds for research, and increasing healthcare expenditure. According to Cancer Research UK, 41,804 new cases of bowel cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of diseases and increasing government funding for the healthcare sector. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Duodenal Cancer Market, by Type
- Adenocarcinoma
- Sarcoma
- Neuroendocrine (carcinoid) tumors
- Lymphoma
Duodenal Cancer Market, by Diagnosis
- Endoscopy or Colonoscopy
- Capsule Endoscopy
- Barium X-Ray
- CT Scan
- MRI Scan
- Other Tests
Duodenal Cancer Market, by Treatment
- Surgery
- Radiotherapy
- Chemotherapy
Duodenal Cancer Market, by Region
- Americas
- North America
- US
- Canada
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
